Gefitinib (ZD1839)

For research use only. Not for use in humans.

目录号：S1025 别名： Iressa 中文名称：吉非替尼

CAS No. 184475-35-2

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173、Tyr992、Tyr1173和Tyr992，IC50 分别为37 nM、37nM、26 nM和57 nM。Gefitinib 可通过阻滞PI3K/AKT/mTOR信号通路来促进肺癌细胞的自噬和细胞凋亡。

规格

价格

库存

购买数量

100mg	RMB 1227.69	现货
250mg	RMB 2205.98	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Gefitinib (ZD1839)发表文献443篇：

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )
Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Elife, 2020, 9e60541

PubMed: 32940599 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01465-y

PubMed: 32978523 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):768

PubMed: 32943616 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )
J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):87

PubMed: 33012785 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Invest New Drugs, 2020, 38(4):1003-1011

PubMed: 31612426 ( click the link to review the publication )

Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13533

PubMed: 32558328 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13670

PubMed: 32956565 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )
Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020,

PubMed: 32843430 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):670

PubMed: 32820157 ( click the link to review the publication )

Exp Mol Med, 2020, 10.1038/s12276-020-0474-1

PubMed: 32728068 ( click the link to review the publication )

Cells, 2020, 9(8):E1830

PubMed: 32756527 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107994

PubMed: 32755586 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Cancer Treat Res Commun, 2020, 25:100229

PubMed: 33152554 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )
J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Mol Cancer, 2019,

PubMed: 31747941 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Cell Prolif, 2019,

PubMed: 31094020 ( click the link to review the publication )
Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Mol Carcinog, 2019,

PubMed: 30811684 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Mediators Inflamm, 2019,

PubMed: 32082070 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )
J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Mol Med Rep, 2019,

PubMed: 31638204 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30975694 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )
Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

EMBO Rep, 2018,

PubMed: 29335246 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018,

PubMed: 29961070 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )
Mol Oncol, 2018, 12(6):883-895

PubMed: 29633504 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):1775-1786

PubMed: 29624806 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Sci, 2018,

PubMed: 29487179 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )
Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Gen Virol, 2018,

PubMed: 29624161 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1311-1320

PubMed: 29907991 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Neuro-oncology, 2017,

PubMed: 28575494 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )
Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Elife, 2017, 6e26733

PubMed: 28737489 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Oncogene, 2017, 36(6):731-745

PubMed: 27477696 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

ACS Infect Dis, 2017, 3(8):564-574

PubMed: 28537707 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28684780 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28939861 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017,

PubMed: 28927099 ( click the link to review the publication )
Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(40):69185-69197

PubMed: 28978189 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28427242 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26640141 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )
Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Anal Biochem, 2016,

PubMed: 27059751 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(31):50258-50276

PubMed: 27384680 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Tumour Biol, 2016,

PubMed: 26286833 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27556697 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )
Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

EMBO Rep, 2015,

PubMed: 26341626 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2947-58

PubMed: 26089022 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25746002 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Cell Death Dis, 2015,

PubMed: 26469972 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26268703 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26639561 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )
Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Mol Med Rep, 2015,

PubMed: 25483995 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23857-73

PubMed: 26160843 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )
Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Int J Biol Sci, 2014,

PubMed: 25013379 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Prostate, 2014, 74(5):528-36

PubMed: 24435707 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):2230-6

PubMed: 25175149 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115144

PubMed: 25502225 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )
PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277177 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )
Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62852

PubMed: 23696788 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 2):435-48

PubMed: 22357970 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )
PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

特性

Gefitinib是有效的EGFR酪氨酸激酶抑制剂。

靶点

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

体外研究

Gefitinib 作用于高和低表达EGFR的细胞系，包括NR6, NR6M 和 NR6W 细胞系，有效抑制EGFR上全部酪氨酸磷酸化位点。磷酸化位点 Tyr1173和Tyr992敏感性较低，需要高浓度Gefitinib才能抑制。Gefitinib作用于NR6W细胞，高效阻断PLC-γ磷酸化, IC50为27nM。NR6wtEGFR 和NR6M细胞系具有低水平PLC-γ磷酸化， IC50 分别为 43 nM和 369 nM。Gefitinib抑制AKT磷酸化，作用于低EGFR和EGFRvIII表达的细胞系， IC50 分别为220 和263nM。Gefitinib按 0.1 到 0.5μM剂量处理，显著促进而不是废除 NR6M细胞形成集落。然而, 2μM Gefitinib 完全抑制 NR6M 集落形成。Gefitinib 作用于高和低EGFR表达的细胞系，EGF 刺激72小时后，快速抑制EGFR 和ERK 磷酸化，这种作用存在剂量依赖性。^[1]Gefitinib抑制 EGF驱动的未转化MCF10A 细胞生长，IC50为 20 nM。^[2] Gefitinib 作用于MDA-MB-231细胞，抑制EGF信号。Gefitinib严重抑制细胞数的增多，这种作用存在剂量依赖性。 ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	NVTG[XV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PNZWlEPTB;MD6wOVQh\|ryP	M1vydlE3PTF4NEez
NIH3T3	MY\GeY5kfGmxbjDBd5NigQ>?	NXvxfnJUOC5{IN88US=>	NHvo[3IzKGh?	NIG3XpdFVVOR	MnWzTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txO	MlWwNVY1QDB{OES=
COS7	MlPYSpVv[3Srb36gRZN{[Xl?	NWfkNJh6QTZizszN			NH;xV4FKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	NHqwPHAyPzF5OEeyNi=>
A549	NVTlXIxPS3m2b4TvfIlkKEG\|c3H5		NVPV[mFCQTZiaB?=	NUm2cWFnTE2VTx?=	MWfJR\|UxRTF\|LkW5JO69VQ>?	M3GwT\|E5OzF\|OEC3
K562	MX\DfZRwfG:6aXOgRZN{[Xl?		MV[5OkBp	NH3BOoNFVVOR	NV3GNZdTUUN3ME25MlM3KM7:TR?=	NVLsVFA1OTh\|MUO4NFc>
MDA-MB-231	MknRR5l1d3SxeHnjJGF{e2G7		MW[5OkBp	NU\yfJN6TE2VTx?=	NH7oUXZKSzVyPUO2MlYyKM7:TR?=	MYCxPFMyOzhyNx?=
MOLT4	NXPCVWhkS3m2b4TvfIlkKEG\|c3H5		M3;XbVk3KGh?	NGL1Z4ZFVVOR	NGjjRZhKSzVyPUG1MlAzKM7:TR?=	NWLzZmNlOTh\|MUO4NFc>
MCF7	NVn2VGRNS3m2b4TvfIlkKEG\|c3H5	MV[1NEDPxE1?	MXu3NkBp		NEfofYRKSzVyPUGyMlA2KM7:TR?=	M1rTS\|E5PzdzOEG5
BT474	M1\zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3XJPFczKGh?		NHPvdZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOFc1KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXSRoIzKHerdHigSWM2OCCxZjCwMlMh\|ryP	MXyxPVAzQDR{NB?=
HN5	NVPIVo9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3SwXlczKGh?		M4DmWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSF61JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKge4l1cCCHQ{WwJI9nKDBwMEGg{txO	MUixPVAzQDR{NB?=
BA/F3	NHXPb2REgXSxdH;4bYMhSXO\|YYm=		NUew[VJ6PzJiaB?=		M3Gx[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6UjDteZRidnRid3n0bEBKSzVyIH;mJFAvODFyODFOwG0>	MWixPVI{QTJ{OR?=
NIH3T3	NUnDWHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEPjOW04OiCq		MnPUS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgUmlJNzOWMzDj[YxteyCneIDy[ZN{cW6pIHXyRlIh\2WwZTD3bZRpKEmFNUCgc4YhOC53NDFOwG0>	M2nxVlE6PjZ3M{e3
MCF7 MX	NFnzeFRHfW6ldHnvckBCe3OjeR?=		MYmzNEBucW5?		MWnJcohq[mm2aX;uJI9nKEKFUmCg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iBzLkGg{txO	NEf2SVMyQTl\|Mkm2NC=>
A431	NVPJUVVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zUVFExKM7:TR?=	NE\BfZQ4OiCq		MWjHTVUxRTBwNUG0JO69VQ>?	M2rVc\|E6QTZ7NE[1
A431	M1y0fWtqdmG\|ZTDBd5NigQ>?	M2flUlAvOSEQvF2=	M4npXVEhcA>?		NXnRdpFJUW6qaXLpeIlwdiCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdg>?	MYexPVk3QTR4NR?=
A431	MoDoT4lv[XOnIFHzd4F6	NXSyOlkyOTByIN88US=>	MnK4NVAhdWmw		MVXQdo9td26pZXSgbY5pcWKrdH;yfUBi[3Srdnn0fUBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	NHfi[nQyQTl4OUS2OS=>
Sf9	M1[4emtqdmG\|ZTDBd5NigQ>?		MmK4NVAhdWmw	MnnhSG1UVw>?	NGPVS3lKdmirYnn0bY9vKG:oIFXHSnIh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemWlZYD0c5Ih[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzNizszN	M1j3bVIxODV4NEK1
NCI-H1975	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYq1JO69VQ>?	M3\UOVczKGh?		M4DyfWlEPTB;OD6yOkDPxE1?	M4W2RVIxOTVzNkew
NCI-H1975	NEX3OYNMcW6jc3WgRZN{[Xl?	MX[xNEDPxE1?			NW\0WHdEUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	M3XrdFIxOTVzNkew
NCI-H1975	M4XhZmZ2dmO2aX;uJGF{e2G7	NFjTd5gyOCEQvF2=			MXLJcohq[mm2aX;uJI9nKEWUQlKyJIF2fG:yaH;zdIhwenmuYYTpc44>	NGO0UG4zODF3MU[3NC=>
NCI-H1975	M3zqS2Z2dmO2aX;uJGF{e2G7	NHL1PHU2KM7:TR?=	MYW0PEBp		NH\xO29KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S1\|	Mk\mNlAyPTF4N{C=
A375	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1TWT\|Q5KGh?		MXvJR\|UxRTJyLkW1JO69VQ>?	MnXzNlA{ODR3M{e=
SMMC7721	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmnyOFghcA>?		NXLYbXI6UUN3ME2zN{4yOiEQvF2=	MVGyNFMxPDV\|Nx?=
DU145	M1mySmN6fG:2b4jpZ{BCe3OjeR?=		NFnnZno2KGR?	M{DkeGROW09?	MYnJR\|UxRTR{LkG3JO69VQ>?	M{i5UFIxPDZ4NUW1
MIAPaCa2	MmXmR5l1d3SxeHnjJGF{e2G7		MU[1JIQ>	MXLEUXNQ	MV3JR\|UxRTVyLk[yJO69VQ>?	M370T\|IxPDZ4NUW1
PANC1	M4C1UGN6fG:2b4jpZ{BCe3OjeR?=		MUm1JIQ>	Mk\zSG1UVw>?	NWPDRnl6UUN3ME20NE41OiEQvF2=	M1;IcVIxPDZ4NUW1
PC9	M4fUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zv[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=	M2HyPVIyOjB6OECy
PC9	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXKbXlWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	Mo[5NlEzODh6MEK=
PC3	NWi2b4JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;zNVAh\|ryP	MUG3NkBp	M2T1WGROW09?	NGT0PZRKSzVyPUeuOEDPxE1?	NVXQboZLOjF\|NUO1OFY>
MDA-MB-468	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[zS\|ExOCEQvF2=	M132SFQ5KGh?	NYnaPWNDTE2VTx?=	M1zUb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5	M3zIS\|IyPDJ7NkOy
Plasmodium falciparum					MYHxTHRUKHC{b3\pcIlv\yCob4KgbY5pcWKrdH;yd{Bw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gdJJwdGmoZYLheIlwdg>?	NIPJO3czOThzN{C0OS=>
NCI-H1993	NWnkdI9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3vGblczKGh?	NFzvZ2ZFVVOR	MX7JR\|UxRTBwMTFOwG0>	M{HUd\|IyQTF4NEOz
NCI-H292	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1T2c\|czKGh?	M4HWUWROW09?	MlXLTWM2OD1yLkCyJO69VQ>?	M3TwXVIyQTF4NEOz
A431	NWL5cFR3U2mwYYPlJGF{e2G7		NWfmXWRkOiCq	Mm\kSG1UVw>?	Mn\MTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDoeY1idiCDNEOxJJdqfGhiSVO1NEBw\iByLkCwNUDPxE1?	NYXISm86OjJzMEGxN\|I>
MCF7	NWD6THVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfQUIlwOTBywrFOwIcwdUx?	NXHzSmxZPDhiaB?=	Ml3lSG1UVw>?	NWDJOlFlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txO	MUGyNlEyQTF\|MB?=
BT474	NXvs[2tiS3m2b4TvfIlkKEG\|c3H5	M3TyO\|ExKM7:TR?=	NFHOeXY1QCCq		NEjxOlVEgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIFLUOFc1KGOnbHzz	NF\FTnczOjF\|OEOwPC=>
MCF7	MVPDfZRwfG:6aXOgRZN{[Xl?	NEKwbmwyOCEQvF2=	M3fERlQ5KGh?		M2jyfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iTVPGO{Bk\WyuczDveoVzNWW6cILld5NqdmdiRYLiRlIh[2WubIO=	MkjvNlIyOzh\|MEi=
HCC827	MV3LbY5ie2ViQYPzZZk>	MV2wMlEzPSEQvF2=	MXqyOEBp	MUnEUXNQ	NH7ZdJJKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	M2DJdlIzOzN7M{Sy
HCC827	MYDLbY5ie2ViQYPzZZk>	NXrjfnRzOC5zMkWg{txO	M{LTclI1KGh?	NH[4SWtFVVOR	NXvZO2FCUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	M4rXelIzOzN7M{Sy
HCC827	MYfLbY5ie2ViQYPzZZk>	M4nhXFAvOTJ3IN88US=>	NV\I[odqOjRiaB?=	MXfEUXNQ	NUGyZYJpUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFHreEBxcG:\|cHjvdplt[XSrb36=	MkfnNlI{Ozl\|NEK=
A431	M{TVbWtqdmG\|ZTDBd5NigQ>?	NXfNW\|hWOTByIN88US=>	NVnNcJdDOzBibXnu		NH\mbJJKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	Mk\6NlI3QTh5OEK=
H460	MXnDfZRwfG:6aXOgRZN{[Xl?		NEXRN3o4OiCq		MYTJR\|UxRTVwNUmg{txO	MVKyNlczPzR2OR?=
HT-29	MVPDfZRwfG:6aXOgRZN{[Xl?		MV[3NkBp		MlryTWM2OD1\|LkO2JO69VQ>?	M2nBVVIzPzJ5NES5
SGC7901	NYrRTlF[S3m2b4TvfIlkKEG\|c3H5		MUW3NkBp		MmH1TWM2OD1zMD6yOkDPxE1?	NHfuXlkzOjd{N{S0PS=>
A498	NUTqd4tNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF2OUigZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKGGwZDDTVmMhf2m2aDDJR\|UxKG:oIEiuOkDPxE1?	NGSyVY0zOjhzOEi0PC=>
Calu3	NIm3SlNEgXSxdH;4bYMhSXO\|YYm=	M2fkblExKM7:Zz;tUC=>	MXK3NkBp		NGK0NYdKSzVyPUGuOkDPxE1?	NXnqbXY3OjNzMU[xOlg>
FADU	M1PCT2N6fG:2b4jpZ{BCe3OjeR?=	MYexNEDPxGdxbVy=	NVLKdplbPzJiaB?=		M1jnWmlEPTB;MD6wOUDPxE1?	MoPkNlMyOTZzNki=
HCC827	Mk\iR5l1d3SxeHnjJGF{e2G7	NEHGOW0yOCEQvHevcWw>	Mn64O\|IhcA>?		MWnJR\|UxRTBwMECxOUDPxE1?	NHXo[JQzOzFzNkG2PC=>
PC9	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXqbVNDOTBizsznM41N	M3vMOFczKGh?		MXTJR\|UxRTBwMEG0JO69VQ>?	MU[yN\|EyPjF4OB?=
Sf9	NFr4TppMcW6jc3WgRZN{[Xl?		NFLoZVgyKGh?	M1zyS2ROW09?	MWLJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC22YXfn[YQhTUeIUjDMPFM1WiCvdYThcpQh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlAyPSEQvF2=	MkTENlM3OTF4OUG=
16HBE14o-	MVPDfZRwfG:6aXOgRZN{[Xl?	NW\XT2M{OTBizszN	NFu5RpM4OiCq	M3ThOGROW09?	MkTqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVZJSkVzNH:tJINmdGy\|IHjhdoJwemmwZzD3bYxlKHS7cHWgSWdHWiCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOTJwN{Gg{txO	M17UUlI{PjZ6NESx
NCI-H1975	NVvZTXMyS3m2b4TvfIlkKEG\|c3H5	NE[2XnQyOCEQvF2=	Mo\EO\|IhcA>?	NUjTdZI6TE2VTx?=	NHTRPVlEgXSxdH;4bYNqfHliYXfhbY5{fCCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB4LkmxO{DPxE1?	M3;YelI{PjZ6NESx
16HBE	M4\5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fJRVczKGh?	NYeyfox4TE2VTx?=	NGjGWYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKge4l1cCCLQ{WwJI9nKDFwNkCxJO69VQ>?	NFnPfZgzOzd7MkOxPC=>
16HBE	NYfNdml{TnWwY4Tpc44hSXO\|YYm=	NInTZWoyODBizszN	Ml\ONVUxKG2rbh?=	NFzaOZJFVVOR	NYqwO4VEUW6mdXP0bY9vKG:oIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKGmwIHj1cYFvKDF4SFLFJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGVITlJ?	NVTlTVVOOjN5OUKzNVg>
A549	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVS3NkBp	MnHTSG1UVw>?	M{PLOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGVITlJxaz3SZZMh\GWyZX7k[Y51KGi3bXHuJGE2PDliY3XscJMhf2m2aDDJR\|UxKG:oIESuOlI3KM7:TR?=	M2H1VlI{Pzl{M{G4
SH-SY5Y	NUPlV2NwS3m2b4TvfIlkKEG\|c3H5		MoPJO\|IhcA>?		MljBTWM2OD1zOD6yNUDPxE1?	NGjaeJIzOzh5MUmwPS=>
LoVo	NV24PGFHU2mwYYPlJGF{e2G7		M17FUFIhKGh?	MUTEUXNQ	NXLuPWhnUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wOlIh\|ryP	NGe5WZgzOzl\|MEm5OC=>
PC9	NVmydWVLU2mwYYPlJGF{e2G7		M33UV\|IhcA>?	NX3tc3g6TE2VTx?=	NX;qXYRDUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=	NUHLdIlzOjN7M{C5PVQ>
HCC827	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnvhO\|IhcA>?		M{fnNWlEPTB;MD6wNVIh\|ryP	M4PsPFI{QTd\|MU[4
A549	MWPLbY5ie2ViQYPzZZk>	MlvENUDPxE1?	MWGxJIg>	MljqSG1UVw>?	MkHuTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFM6QSEQvF2=	NInPZm0zOzl6OEO1OC=>
A549	NU[yd29UTnWwY4Tpc44hSXO\|YYm=	MkfsNUDPxE1?	NVrrXZp7OSCq	NEDNWFRFVVOR	NFm4Z49E\WyudXzhdkB2eHSja3W=	MWCyN\|k5QDN3NB?=
HCC827	NULCUFFTU2mwYYPlJGF{e2G7	MVOwMlUh\|ryP	M3zhSlIhcA>?	M1[1N2ROW09?	NEHKV2tKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	Ml\HNlM6QTN\|Mki=
HCC827	MX3GeY5kfGmxbjDBd5NigQ>?	Mk\KNE42KM7:TR?=	NVq0c25NOiCq	NVLPb402TE2VTx?=	NIjtRWZKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=	MWCyN\|k6OzN{OB?=
HCC827	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M32zc\|ExKM7:TR?=	NVvNRYxIPzJiaB?=	MYjEUXNQ	NH\yXnZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIdm\mm2aX7pZk1{\W6\|aYTpeoUhcHWvYX6gTGNEQDJ5IHPlcIx{KGijcnLvdolv\yCHR1\SJGU4PDZidH:gRVc2OCCmZXzleIlwdiC5aYToJGlEPTBib3[gNE4xODV6MTFOwG0>	NFnSb2szPDB3M{[3OC=>
A431	NHrFXW9McW6jc3WgRZN{[Xl?	NF7lSJcyODBizszN	MX2zNEBucW5?		NVnLR5l4UW6qaXLpeIlwdiCxZjDFS2ZTKGmwIIPo[YQhdWWvYoLhcoUhfmW\|aXPs[ZMhf2m2aDDJR\|UxKG:oIEGuNUDPxE1?	MXWyOFA6PDR\|Mh?=
BCRP-MDCK2	MXrGeY5kfGmxbjDBd5NigQ>?	NV3ldoJxOS56IN88US=>	MYi3NkBp	MWXEUXNQ	MnTpTY5kemWjc3Wgc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	MX6yOFE5PDJzMx?=
BCRP-MDCK2	NXfZd3FYTnWwY4Tpc44hSXO\|YYm=	Mn;xNU45KM7:TR?=	MYW3NkBp	Ml20SG1UVw>?	MXTS[YR2[3Srb36gc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	MWOyOFE5PDJzMx?=
MDCK	MYrDfZRwfG:6aXOgRZN{[Xl?		MUG3NkBp	MUnEUXNQ	M1Xlc2dKPTB;MT60OUDPxE1?	MkD6NlQyQDR{MUO=
MDCK2	NWHoenE5TnWwY4Tpc44hSXO\|YYm=	MXyxMlgh\|ryP	NYHITJpVPzJiaB?=	NUDBXHQzTE2VTx?=	NXXp[XRtUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2LQJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCKb3XjbJN1KDN\|M{SyJIFk[3WvdXzheIlwdiC5aYToJGlEPTBib3[gN{4yQSEQvF2=	MV6yOFE5PDJzMx?=
A431	MonvR5l1d3SxeHnjJGF{e2G7		NIryd\|U4OiCq	MmfrSG1UVw>?	NFrTfW1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGW6cILld5NqdmdiRVfGVkB4cXSqIFnDOVAhd2ZiMD61OUDPxE1?	NEHHWnUzPDRzMUGyNy=>
Calu3	Mn7WR5l1d3SxeHnjJGF{e2G7		NXTtOlJ1PzJiaB?=	MmixSG1UVw>?	M4\ET2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNidHV\|IHPlcIx{KGW6cILld5NqdmdiSFXSNkB4cXSqIFnDOVAhd2ZiMD65PUDPxE1?	MnrHNlQ1OTFzMkO=
KB	NYPLW4NDU2mwYYPlJGF{e2G7	M1rEWFExKM7:TR?=	M1e0cVEhcA>?	M{[5V2ROW09?	NGXMWFRKdmirYnn0bY9vKG:oIFXHSk1{fGmvdXzheIVlKGG3dH;wbI9{eGixconsZZRqd25ib3[gSWdHWiC5aYToJGlEPTBib3[gNE4xOjVizszN	NHW4VlEzPDRzMUGyNy=>
BEAS2B	NULVWlZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnYe242OCEQvF2=	MYm3NkBp	MVTEUXNQ	NWXtZm4yUUN3ME2xN{46PCEQvF2=	NIfQcJEzPDZyN{W5NS=>
NCI-H1975	NUDDTGd5TnWwY4Tpc44hSXO\|YYm=	NUftemNPOTByIN88US=>	MkTZNVUxKG2rbh?=	NUT1XHhjTE2VTx?=	MnTaTY5lfWO2aX;uJI9nKE6RIIDyc4R2[3Srb36gbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfA>?	NHPtfnMzPDZyN{W5NS=>
Hela	NUPnPYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYCyOEBp	MWrEUXNQ	Mlf0TWM2OD1{Lk[3JO69VQ>?	MViyOFc{OTJ6MR?=
HepG2	M3zHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmX4NlQhcA>?	NITpPIRFVVOR	NXnBTJI6UUN3ME22MlQzKM7:TR?=	NEewUm8zPDd\|MUK4NS=>
Sf9	NETqU3NMcW6jc3WgRZN{[Xl?		NIHob4wyOCCvaX6=	M33IbWROW09?	NIrCXYtKdmirYnn0bY9vKG:oIHH1eI9xcG:\|cHjvdplt[XSrb36gc4YhemWlb33ibY5idnRiaHnzMZRi\2enZDDFS2ZTKCijbXnuc{Bi[2mmIE[0OU0yOTh4KTDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMEKg{txO	MYCyOFc{OTJ6MR?=
SW620	M2ThT2N6fG:2b4jpZ{BCe3OjeR?=		NVfCRpNHPDhiaB?=	M1;J[GROW09?	NVrxOXF2UUN3ME2yPE4zKM7:TR?=	NVLrfVhHOjR7MEC1PVQ>
HCC827	NEDzNYtHfW6ldHnvckBCe3OjeR?=	MlS5NE42KM7:TR?=	NXzs[HFDOiCq	M2rJO2ROW09?	MVTkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdg>?	MX2yN\|k6OzN{OB?=
HCC827	M4XFcGZ2dmO2aX;uJGF{e2G7	M4HNTVAvPSEQvF2=	M2n2WlIhcA>?	MUTEUXNQ	NHT1T3pld2W\|IH7veEBqdmirYnn0JIMuVWW2IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicES0M\|QzKHCqb4PwbI9zgWyjdHnvci=>	NHfuVVEzOzl7M{OyPC=>
HCC827	M{HFTGN6fG:2b4jpZ{BCe3OjeR?=	NYfEXnNUOC53IN88US=>	MUO3NkBp	MlPCSG1UVw>?	M2Ptb4hieyCwbzDjfZRwfG:6aXPpeJk>	NYnmWYpZOjN7OUOzNlg>
NCI-H1975	NWDuPGJiTnWwY4Tpc44hSXO\|YYm=	M2DhblExKM7:TR?=	MnO2PEBp	MVPEUXNQ	Mmr4[I9meyCwb4SgbY5pcWKrdHmgSWdHWiCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdg>?	M17ESlI{OTF4MU[4
A431	NFOyT\|NMcW6jc3WgRZN{[Xl?	MkTINUDPxE1?	M2jjc\|EhcA>?	NXrQZ2pWTE2VTx?=	M4XJVIhieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	MkHSNlQ6ODB3OUS=
LNCaP	MnXhSpVv[3Srb36gRZN{[Xl?	MWqxNEDPxE1?	NWK1e4pbOmhib4KgOEBp	M1[3bWROW09?	NWDScG5N\G:nczDuc5QhcW6qaXLpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIHntcZVvd3C3cnnmbYVlKG[uYXeteIFo\2WmIFLtfEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|MmDdRXRR	M2PhU\|E5PjZ5M{Gy
H1975	NXW4cpZjU2mwYYPlJGF{e2G7	Mn\XNUDPxE1?	Ml7rNlQhcA>?	NIryfnZFVVOR	NWXZbZBp\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	NILVdm4zPDZyN{W5NS=>
H1975	MWHGeY5kfGmxbjDBd5NigQ>?	M3X6WlEh\|ryP	NHTGVYQzPCCq	MlzVSG1UVw>?	M3vLc4Rw\XNibn;0JIlvcGmkaYSgSXJMKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVQ>?	MYWyOFYxPzV7MR?=
HCC827	NXjDcnR3U2mwYYPlJGF{e2G7	NE\KRZUxNjFzIN88US=>	NHrZb44yKGh?	NXTrelNsTE2VTx?=	M1T4VohieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG\|c3Xzd4VlKGG\|IILlZ493\XK7IH;mJGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbh?=	M3:1Z\|I1OTJ2OEm4
H1975	NXvUb\|hnU2mwYYPlJGF{e2G7	M1TlUVAvOzNizszN	MkGxNkBp	MonVSG1UVw>?	MUPkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRWtVKHCqb4PwbI9zgWyjdHnvci=>	MWqyOFEzPDh7OB?=
H1975	M17DN2tqdmG\|ZTDBd5NigQ>?	NU[0U41COC5\|MzFOwG0>	MoXhNkBp	MUjEUXNQ	M1XmfIRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	MVOyOFEzPDh7OB?=
H1975	Mn20T4lv[XOnIFHzd4F6	NYq5cWE6OC5\|MzFOwG0>	NX\ifZdlOiCq	MX7EUXNQ	NFHzWWxld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCyaH;zdIhwenmuYYTpc44>	MWqyOFEzPDh7OB?=
H1975	MWLLbY5ie2ViQYPzZZk>	MnfDNE4yOjVizszN	MYWyOEBp	MmKxSG1UVw>?	M3\oPIRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	NYPoeGhHOjJ\|M{mzOFI>
H1975	MX\LbY5ie2ViQYPzZZk>	M2D2RlAvPSEQvF2=	NVHacnEzOjRiaB?=	MmW4SG1UVw>?	MXHkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEW{azDwbI9{eGixconsZZRqd25?	M1qwSFIzOzN7M{Sy
H1975	NGn1[JJMcW6jc3WgRZN{[Xl?	MoexNE42KM7:TR?=	NG\4ZYYzPCCq	Mlu2SG1UVw>?	M{DRRoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MX[yNlM{QTN2Mh?=
MIAPaCa2	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorHNk42KM7:TR?=	NIHPW444OiCq	M{X4W2ROW09?	NWPDPYFVcGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	M4LCSlIxPDZ4NUW1
MIAPaCa2	M{fKSmN6fG:2b4jpZ{BCe3OjeR?=	NFv1VokyKM7:TR?=	Mnr1NVAh\A>?	MYHEUXNQ	MUfoZZMhdm9iY4n0c5RwgGmlaYT5JIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINwdG:weTDmc5Ju[XSrb36=	NEm4Zm0zODR4NkW1OS=>
MIAPaCa2	NYrVVVlpSXCxcITvd4l{KEG\|c3H5	MWSxNEDPxE1?	NFTR[IEzPGhib4KgOFghcA>?	NYW1XZdrTE2VTx?=	MlTZ[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NFrXeXozODR4NkW1OS=>
MIAPaCa2	MYHBdI9xfG:\|aYOgRZN{[Xl?	MXmyNEDPxE1?	NX7B[2lYOjRiaB?=	NF7XTpBFVVOR	NWG0cmk6\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyClYYPwZZNmKDNiYXP0bZZifGmxbh?=	NHvtb20zODR4NkW1OS=>
EoL-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PFN2lEPTB;NT6xO{BvVQ>?	MnntV2FPT0WU
NCI-H720	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGX5UmVKSzVyPUK2MlkzKG6P	MlL6V2FPT0WU
NCI-SNU-5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XIcmlEPTB;MkiuNVkhdk1?	NVfG[\|FVW0GQR1XS
EW-3	NYH1Z3ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzITWM2OD12Nj6wOEBvVQ>?	NWX6XFU2W0GQR1XS
HCC2218	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDuNYxKSzVyPUWwMlU6KG6P	NYjKNllHW0GQR1XS
HuO-3N1	MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\SRpNKSzVyPUW2MlA6KG6P	NF;Hc2FUSU6JRWK=
DB	NEnER41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHy0VphKSzVyPU[wMlk3KG6P	M4TmNXNCVkeHUh?=
HSC-4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTZzLkWzJI5O	Ml3XV2FPT0WU
DOK	NIrqbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWX3WG1SUUN3ME25N{43OiCwTR?=	MYXTRW5ITVJ?
H9	NVjJU4pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPtU4NKSzVyPUGzO{4zKG6P	M3z2fnNCVkeHUh?=
NCI-H292	NV3jZ2VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTF4Mj62OkBvVQ>?	MXLTRW5ITVJ?
HSC-2	NFn4VG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP2epE6UUN3ME2xOlUvPTdibl2=	MoXQV2FPT0WU
LU-65	NXrMZ3drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTF4Nj62NUBvVQ>?	MlfsV2FPT0WU
BV-173	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXxb4tKSzVyPUG4Ok42PSCwTR?=	M{PSc3NCVkeHUh?=
LB2241-RCC	NEHFVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3iWYRCUUN3ME2xPVQvQTNibl2=	NVTwPHpKW0GQR1XS
KG-1	M2\pV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jtZWlEPTB;MkC0MlM1KG6P	MnLRV2FPT0WU
CHL-1	NULIUohtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn1S3NwUUN3ME2yNFgvPTFibl2=	NFvYOYdUSU6JRWK=
KYSE-140	NGCwOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXqT3NKSzVyPUKwPU46PiCwTR?=	MnnHV2FPT0WU
DU-145	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJzOT6wOEBvVQ>?	M2j6enNCVkeHUh?=
EW-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJ{NT6xJI5O	NVn5S3NSW0GQR1XS
KYSE-450	M2HWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LoVGlEPTB;MkS3MlkzKG6P	NEDTfJBUSU6JRWK=
CAL-72	NGXkcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{myOWlEPTB;Mk[4Mlc{KG6P	MVzTRW5ITVJ?
MEG-01	NFzz[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH20c\|FKSzVyPUK3Ok44PiCwTR?=	MX;TRW5ITVJ?
HCE-T	MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;2cVZKSzVyPUK3PU44QSCwTR?=	MYXTRW5ITVJ?
NCI-SNU-1	M{LEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTJ6Mz6zNkBvVQ>?	NVP6eVlXW0GQR1XS
CAL-27	NEfFOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXnTWM2OD1{OEmuNFghdk1?	NEe0blVUSU6JRWK=
BALL-1	M33XOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFn1cWJKSzVyPUK5O{41OiCwTR?=	MXfTRW5ITVJ?
SBC-1	M3[4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH0OopKSzVyPUOwO{44QSCwTR?=	MkWzV2FPT0WU
CAL-54	NUOwRXFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTNzMT6yN{BvVQ>?	Ml;uV2FPT0WU
TI-73	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTNzMj63OUBvVQ>?	NEXHc5VUSU6JRWK=
P12-ICHIKAWA	NFnDOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVG3R3hDUUN3ME2zNlgvODZibl2=	Mk\0V2FPT0WU
ACHN	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTN\|MT60JI5O	NXPxU4RWW0GQR1XS
PC-14	NFLmR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mom5TWM2OD1\|M{OuOFEhdk1?	MVXTRW5ITVJ?
HCC1806	NXSxXJVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPaTWM2OD1\|M{euOVEhdk1?	M3ToOXNCVkeHUh?=
SK-MEL-24	M3HmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmH5TWM2OD1\|M{euPFchdk1?	NHq3bplUSU6JRWK=
A4-Fuk	MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTN3MD6wNkBvVQ>?	MVrTRW5ITVJ?
ECC10	Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7LTmJKSzVyPUO1Nk46PiCwTR?=	M3vHXnNCVkeHUh?=
KASUMI-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW3TWM2OD1\|Nk[uO\|Mhdk1?	MlHjV2FPT0WU
CAL-33	M4q4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGO5PIJKSzVyPUO3NE46KG6P	Mn;OV2FPT0WU
MDA-MB-175-VII	M3qw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\rTWM2OD1\|N{iuPFghdk1?	NVjKTIRHW0GQR1XS
NUGC-3	M1;zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHGXGl5UUN3ME20NFEvQDFibl2=	MnnBV2FPT0WU
KY821	NVfhd5dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2H3cGlEPTB;NEC4MlU4KG6P	NXfNPFNNW0GQR1XS
CTB-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTR{ND60JI5O	NWLDd4ZHW0GQR1XS
DoTc2-4510	NYPqZnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfIZWJKSzVyPUS0Nk4yOiCwTR?=	MoLPV2FPT0WU
EFO-27	NUW3W251T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPuTWM2OD12NUSuO\|Qhdk1?	MmrCV2FPT0WU
BPH-1	NVXBVWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjNcIFKSzVyPUS5NU4yPiCwTR?=	M2nVXHNCVkeHUh?=
KYSE-270	M{DsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DGTGlEPTB;NEm4MlY2KG6P	NFrwXnpUSU6JRWK=
HO-1-N-1	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTVyOT6yOUBvVQ>?	Mmj1V2FPT0WU
SK-MEL-1	M1L4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m2T2lEPTB;NUGwMlk6KG6P	M3rCV3NCVkeHUh?=
MOLT-13	M4TIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTUfFRKSzVyPUWxOE45OiCwTR?=	NHr2V\|hUSU6JRWK=
TK10	NWfmR2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkL4TWM2OD13MUWuNVEhdk1?	M4fEOHNCVkeHUh?=
HN	NW[xSWQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzpTWM2OD13MUeuN\|ghdk1?	MUXTRW5ITVJ?
SCC-15	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTV{NT62PEBvVQ>?	NFXLe45USU6JRWK=
NCI-H358	MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHVTWM2OD13MkeuOlYhdk1?	NH7ZWo1USU6JRWK=
KYSE-180	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HWXmlEPTB;NUOwMlYzKG6P	MWjTRW5ITVJ?
NCI-H82	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DqbGlEPTB;NUSwMlUhdk1?	NIHKPWpUSU6JRWK=
NB7	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfMbGFKSzVyPUW0Ok4{OiCwTR?=	MYLTRW5ITVJ?
DSH1	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f1dWlEPTB;NU[2Mlg5KG6P	NGewRZFUSU6JRWK=
RS4-11	NUHFW\|hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHKfVRKSzVyPUW2PE42QSCwTR?=	MkDZV2FPT0WU
CAN	NIPPXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTV6MD63OkBvVQ>?	NYTjc5NZW0GQR1XS
Ca9-22	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTV6OD62OEBvVQ>?	NFL1NnVUSU6JRWK=
CAL-39	NXHNUJB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTV7Nj6zJI5O	M4HGV3NCVkeHUh?=
NCI-H1623	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PwcmlEPTB;NUm5MlM3KG6P	Ml35V2FPT0WU
FADU	M2KycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn:3TWM2OD14MESuOlkhdk1?	M4rIcHNCVkeHUh?=
NB69	NInyNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTTOXZpUUN3ME22NVQvOzVibl2=	M2DWU3NCVkeHUh?=
Ramos-2G6-4C10	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HsbmlEPTB;NkKxMlQ3KG6P	M17tcHNCVkeHUh?=
LB1047-RCC	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHqSZFKSzVyPU[yOU4zQSCwTR?=	NWrSOHE1W0GQR1XS
MV-4-11	NXr6SoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TnWWlEPTB;NkK3Mlchdk1?	M2faNnNCVkeHUh?=
DBTRG-05MG	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkO4TWM2OD14M{KuNlghdk1?	M1rzfnNCVkeHUh?=
ME-180	M2XKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVO3XIdQUUN3ME22N\|IvQSCwTR?=	MlfPV2FPT0WU
NBsusSR	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTITWM2OD14NE[uOVIhdk1?	NHnqWJZUSU6JRWK=
COR-L105	M3;zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXZTWM2OD14NkKuOVMhdk1?	M37lNnNCVkeHUh?=
ETK-1	M3vO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTZ4Mj61PUBvVQ>?	NYHScWJzW0GQR1XS
L-363	M2\Jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTZ5MT65OEBvVQ>?	NUn2bVlLW0GQR1XS
LU-134-A	NUL4ZnhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTdzOT6wPUBvVQ>?	M2O4[HNCVkeHUh?=
NCI-H1770	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TlTWlEPTB;N{KyMlQhdk1?	NVvoSmhXW0GQR1XS
HAL-01	M3\NSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoriTWM2OD15M{SuO\|Ehdk1?	NWfTcopuW0GQR1XS
COLO-684	M4TC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rrVGlEPTB;N{WzMlAyKG6P	M{KyPXNCVkeHUh?=
TE-6	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTCTWM2OD15NkSuN\|Ehdk1?	MWrTRW5ITVJ?
A431	NFLCZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTd6MD6wOEBvVQ>?	NH7FXGNUSU6JRWK=
LU-135	M3z4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInNV2tKSzVyPUe4N{4xOyCwTR?=	NVrCcGRLW0GQR1XS
EC-GI-10	NFPNTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TyOGlEPTB;N{i4MlUzKG6P	M1fKdnNCVkeHUh?=
TE-12	M3zi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnwfItKSzVyPUiyNU4yOSCwTR?=	NH\FPGVUSU6JRWK=
LoVo	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTh3OT6wOkBvVQ>?	MVTTRW5ITVJ?
23132-87	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIH1R5NKSzVyPUi2OE4zQCCwTR?=	MoTJV2FPT0WU
AU565	NYXORnhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmT0TWM2OD16NkmuOkBvVQ>?	NWLFUIRQW0GQR1XS
DEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTh5Nz62OUBvVQ>?	NGX5coxUSU6JRWK=
COR-L88	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW1SHZlUUN3ME24PFIvOjZibl2=	Mkj3V2FPT0WU
NCI-H2126	MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPBbFhMUUN3ME24PFIvQDNibl2=	MlzIV2FPT0WU
CAPAN-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTh6Mz6yPUBvVQ>?	M1zoTnNCVkeHUh?=
BT-474	NHvzZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPXV\|ZtUUN3ME25N\|gvOTRibl2=	Mk\sV2FPT0WU
BHY	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLEdGVOUUN3ME25O\|UvPDhibl2=	M4jYfnNCVkeHUh?=
HT-3	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTl6Mj60NUBvVQ>?	MmTOV2FPT0WU
SK-NEP-1	NITtXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3qxTmlEPTB;OUi5MlQ1KG6P	NYPONYJlW0GQR1XS
MS-1	M4HxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTEc5dLUUN3ME25PVQvPjlibl2=	NFX4bZVUSU6JRWK=
DOHH-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGn6XFVKSzVyPUGuNFAxOjFizszN	MlqxV2FPT0WU
NCI-H1304	M4\GXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUiwW5ZOUUN3ME2xMlAyPjR\|IN88US=>	NXKzOFRJW0GQR1XS
EM-2	M3\meGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH6WYVKSzVyPUGuNFMxOTZizszN	M{L0NXNCVkeHUh?=
MHH-PREB-1	NVzsTo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnmPWhyUUN3ME2xMlA5PDVzIN88US=>	MkHhV2FPT0WU
KU-19-19	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEL1cHRKSzVyPUGuNFg2PDFizszN	NIDhSIhUSU6JRWK=
NCI-H1648	NHPQbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fiWGlEPTB;MT6xNFYyPiEQvF2=	MUnTRW5ITVJ?
MKN1	Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nQdmlEPTB;MT6yNVk5PyEQvF2=	Ml:wV2FPT0WU
SNU-449	NXvvTWZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTFTWM2OD1zLkKyNlA5KM7:TR?=	M363RnNCVkeHUh?=
OAW-42	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjhdWlnUUN3ME2xMlI4QDJ3IN88US=>	NYPVSYN3W0GQR1XS
769-P	M{jvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jjRWlEPTB;MT6yO\|kyQCEQvF2=	M4S4PHNCVkeHUh?=
SW1088	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXk[oNKSzVyPUGuNlk3ODdizszN	M4jrcnNCVkeHUh?=
GCIY	NF;QcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfCTWM2OD1zLkOwNVMzKM7:TR?=	M{DzbHNCVkeHUh?=
CTV-1	MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;WSo5xUUN3ME2xMlMxQCEQvF2=	M2PFb3NCVkeHUh?=
NCI-H1092	NHT6TZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu1TGZKSzVyPUGuN\|A5PSEQvF2=	MnrTV2FPT0WU
NKM-1	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{izN2lEPTB;MT6zNlU6PyEQvF2=	MV7TRW5ITVJ?
NCI-H1650	NFrpc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjHTWM2OD1zLkOzOFgzKM7:TR?=	MXLTRW5ITVJ?
SW954	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfETWM2OD1zLkO0NFQ5KM7:TR?=	MmjVV2FPT0WU
SW48	M1LjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTFwM{[2NVgh\|ryP	NWfPXG9MW0GQR1XS
SK-N-DZ	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTFOYwzUUN3ME2xMlM3QTR5IN88US=>	MXjTRW5ITVJ?
KMOE-2	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFwM{m4NVUh\|ryP	MnT3V2FPT0WU
NB5	MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTFwNEC4PVQh\|ryP	NX\6VFRlW0GQR1XS
CCRF-CEM	Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfVTWM2OD1zLkSxNVEh\|ryP	MoHkV2FPT0WU
RH-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Tac2lEPTB;MT60NVE{PiEQvF2=	MkfuV2FPT0WU
NCI-H526	NIrLfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTFwNEO4NlYh\|ryP	NWHEc2tVW0GQR1XS
697	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTFwNESxNFQh\|ryP	NVXQSZd5W0GQR1XS
J82	NVrtfmlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV21VFc6UUN3ME2xMlQ2PzZ4IN88US=>	MUTTRW5ITVJ?
BE-13	NFXaVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfHd3J7UUN3ME2xMlUxPjdzIN88US=>	MljoV2FPT0WU
SAS	M2jub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nkdmlEPTB;MT61NVYzOiEQvF2=	NY\pbIVIW0GQR1XS
SCC-25	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzvS2JVUUN3ME2xMlUzOzJ{IN88US=>	M3fKT3NCVkeHUh?=
LAMA-84	M4fPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3THSGlEPTB;MT61N\|gyPSEQvF2=	MYnTRW5ITVJ?
HSC-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnLfpd{UUN3ME2xMlU1OzhizszN	MnrGV2FPT0WU
BT-549	M1zY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDPXIZKSzVyPUGuOVg4PDdizszN	MkW5V2FPT0WU
ML-2	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjZTGNWUUN3ME2xMlY1ODJ7IN88US=>	NITYT4pUSU6JRWK=
BB30-HNC	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrER29KSzVyPUGuOlg6PzJizszN	NV7vW41JW0GQR1XS
PANC-03-27	NYTIdlhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrlXFdKSzVyPUGuO\|AyOzlizszN	MoS1V2FPT0WU
COLO-678	NHvZUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXtcmZ{UUN3ME2xMlc{PDR2IN88US=>	M2rwS3NCVkeHUh?=
NCI-H1666	NGrxNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3nTWM2OD1zLke0O\|A1KM7:TR?=	NHHpTVZUSU6JRWK=
NCI-H209	M{jmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTjTWM2OD1zLke3NlY6KM7:TR?=	NF7kZXRUSU6JRWK=
EPLC-272H	M1L2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFwOEW1OFkh\|ryP	MnTSV2FPT0WU
OMC-1	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XmOWlEPTB;MT65PVg5QCEQvF2=	NWrieJZJW0GQR1XS
HCC70	Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfsS4dVUUN3ME2yMlAxQDF3IN88US=>	Mm\rV2FPT0WU
CAL-12T	M4\PNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHUTWM2OD1{LkCxPFYyKM7:TR?=	NIGw[ZNUSU6JRWK=
TGBC24TKB	M4XQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O5dGlEPTB;Mj6wNlk3OSEQvF2=	NWO2UGw3W0GQR1XS
EKVX	M1fCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFG1TpNKSzVyPUKuNFQ6OzlizszN	NGPvXZRUSU6JRWK=
SW1116	NGnI[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYSzfJhYUUN3ME2yMlA3ODB7IN88US=>	MnXTV2FPT0WU
NCI-H2009	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TtcmlEPTB;Mj6wOlIyPCEQvF2=	NHXiem9USU6JRWK=
RPMI-8866	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;hcnRwUUN3ME2yMlA5PDhzIN88US=>	MX\TRW5ITVJ?
KARPAS-45	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJwMUK0O\|kh\|ryP	NVn4VWpRW0GQR1XS
RXF393	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moe3TWM2OD1{LkGzNFM3KM7:TR?=	MX;TRW5ITVJ?
786-0	NEDvR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTJwMUi0NFYh\|ryP	MV\TRW5ITVJ?
SCC-4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfBeIJ3UUN3ME2yMlIyPzd4IN88US=>	MUXTRW5ITVJ?
BT-20	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPFTWM2OD1{LkK2O\|Q1KM7:TR?=	NEHMVW1USU6JRWK=
A498	NW\UNW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjOe3JuUUN3ME2yMlI6PDF3IN88US=>	NVPpTVZQW0GQR1XS
IGROV-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjmTWM2OD1{LkOxNlM4KM7:TR?=	NVzOOY44W0GQR1XS
JVM-3	M17uV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTuWZdiUUN3ME2yMlM1PjR\|IN88US=>	MlnQV2FPT0WU
NCI-H2170	NWCwTGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjPT5pHUUN3ME2yMlM1Pzh\|IN88US=>	NUT2bYJ5W0GQR1XS
EW-18	M4SwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn0TWM2OD1{LkO1OFcyKM7:TR?=	MkP1V2FPT0WU
KU812	NWj6UIMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG1cGhKSzVyPUKuN\|Y4PzlizszN	NH7qO2tUSU6JRWK=
NY	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPVTWM2OD1{LkO3Nlch\|ryP	NGXQd\|RUSU6JRWK=
HTC-C3	NInlZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3sbmVDUUN3ME2yMlQzOjZ5IN88US=>	MnW1V2FPT0WU
CFPAC-1	NFvC[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3l[XBKSzVyPUKuOFM5PjRizszN	NVfPOFBJW0GQR1XS
HH	M2X2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDJWWdrUUN3ME2yMlQ6QDV2IN88US=>	M3mwc3NCVkeHUh?=
MKN7	NYn5Vnp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPmRplKSzVyPUKuOlI4PDhizszN	M1\1OXNCVkeHUh?=
TE-8	M1nKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTJwNkO2OVMh\|ryP	NGTrWIdUSU6JRWK=
MC-IXC	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTJwNkS0OVMh\|ryP	M3v2fnNCVkeHUh?=
DMS-79	M4XudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJwNkmyPFQh\|ryP	MnnHV2FPT0WU
Detroit562	NF[xW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\TfmlEPTB;Mj62PVg1PSEQvF2=	NFHoW2dUSU6JRWK=
HuP-T4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PIdGlEPTB;Mj63NlgyQCEQvF2=	Mki4V2FPT0WU
QIMR-WIL	NFLDO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PlSmlEPTB;Mj63OVk2OiEQvF2=	M2TscnNCVkeHUh?=
BB65-RCC	M4rvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnEUXNKSzVyPUKuPFA4OTNizszN	NIXxeVlUSU6JRWK=
PC-3	NVK5c5plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlGyTWM2OD1{LkizN\|E4KM7:TR?=	M{jUVnNCVkeHUh?=
OVCAR-3	NI\BSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLqW3ZKSzVyPUKuPFU2QTRizszN	NVrXcmF{W0GQR1XS
KYSE-510	NIDDV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HuVGlEPTB;Mj64Olc5PiEQvF2=	M32zcXNCVkeHUh?=
HC-1	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTYTWM2OD1{Lkm0NFEzKM7:TR?=	NYXOVohqW0GQR1XS
NCI-H1693	NH\sO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnVTWM2OD1{Lkm1PFk4KM7:TR?=	MorMV2FPT0WU
DU-4475	M3r5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\TTWM2OD1{Lkm5NFUzKM7:TR?=	NGXGcHJUSU6JRWK=
COLO-680N	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnkbnBKSzVyPUOuNFA1QTVizszN	NH;XTm5USU6JRWK=
MN-60	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTNwMES5O\|Qh\|ryP	MVLTRW5ITVJ?
BCPAP	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorMTWM2OD1\|LkC4Nlk2KM7:TR?=	NIrRS4ZUSU6JRWK=
647-V	NWPPVXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTNwMU[yNkDPxE1?	NFr4[W9USU6JRWK=
HT-1376	NVX5[2ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTCTWM2OD1\|LkKwOVA3KM7:TR?=	NGXpR4ZUSU6JRWK=
NCI-H1793	NGXsVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELkWnVKSzVyPUOuNlExQThizszN	M{S4R3NCVkeHUh?=
SW1463	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXIbFJKSzVyPUOuNlYyQTJizszN	NEPhdZdUSU6JRWK=
NCI-H727	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG[5UWFKSzVyPUOuN\|g2QDRizszN	MYHTRW5ITVJ?
LB771-HNC	M1P2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHLR29KSzVyPUOuN\|kyOjZizszN	MYXTRW5ITVJ?
D-542MG	NVf5fGxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm1TWM2OD1\|LkS0NlIzKM7:TR?=	MUHTRW5ITVJ?
NTERA-S-cl-D1	NFn2b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjlTWM2OD1\|LkS0PVU4KM7:TR?=	Mnv1V2FPT0WU
C8166	NFTJOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTNwNE[1NlEh\|ryP	MkXtV2FPT0WU
639-V	NX;DS2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjGRphKSzVyPUOuOVc4QTJizszN	NHXPbFVUSU6JRWK=
TE-1	Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfZTWM2OD1\|LkW5NVY6KM7:TR?=	Mlf5V2FPT0WU
OAW-28	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fCN2lEPTB;Mz61PVQzPiEQvF2=	MkD4V2FPT0WU
SK-LU-1	NEXvdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTNwNkC2OFUh\|ryP	M3PmS3NCVkeHUh?=
CaR-1	NFjQTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlr2TWM2OD1\|Lk[xNFQ5KM7:TR?=	NHLDOINUSU6JRWK=
A2780	NGfzeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DQVmlEPTB;Mz62OFA5QSEQvF2=	NHHMOlJUSU6JRWK=
C2BBe1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlq5TWM2OD1\|Lk[0OFA4KM7:TR?=	M3LNcnNCVkeHUh?=
SK-MES-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjqTWM2OD1\|Lk[0OlE1KM7:TR?=	NFyzZ4hUSU6JRWK=
PANC-10-05	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\pcYNKSzVyPUOuO\|IxPzJizszN	MVnTRW5ITVJ?
J-RT3-T3-5	M4fMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzlTWM2OD1\|Lke1OFA3KM7:TR?=	MUPTRW5ITVJ?
ES4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELKW3pKSzVyPUOuPFIzQDZizszN	MXHTRW5ITVJ?
NCI-H28	M1;1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXtb4duUUN3ME2zMlgzQTZzIN88US=>	MlfBV2FPT0WU
NCI-H1155	NH\KPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTNwOESxOVkh\|ryP	M13mNHNCVkeHUh?=
KURAMOCHI	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlW4TWM2OD1\|Lki2NFU3KM7:TR?=	NGj6OYtUSU6JRWK=
NCI-H69	M3zVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjGO\|V7UUN3ME2zMlkxOTd6IN88US=>	MULTRW5ITVJ?
IST-MES1	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS3ZWYyUUN3ME2zMlk1ODJ7IN88US=>	M1;BfHNCVkeHUh?=
NH-12	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF2x[ppKSzVyPUOuPVQyQDdizszN	MoC0V2FPT0WU
JVM-2	M1nKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zlcmlEPTB;Mz65OFc2OiEQvF2=	MXTTRW5ITVJ?
EW-16	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnX1TWM2OD1\|Lkm1OVc4KM7:TR?=	MWTTRW5ITVJ?
NCI-H441	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fNOGlEPTB;Mz65O\|AyPCEQvF2=	Mmf5V2FPT0WU
RCC10RGB	NGDldFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;CSmFkUUN3ME20MlAyOjR4IN88US=>	MVHTRW5ITVJ?
TCCSUP	NIj1UIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vHSmlEPTB;ND6xNVA2KM7:TR?=	NWnrWmsxW0GQR1XS
HL-60	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXtUVIxUUN3ME20MlEzOjRzIN88US=>	M3vrRnNCVkeHUh?=
EW-11	NXi4fFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTRwMUOyOlEh\|ryP	NHS0SlNUSU6JRWK=
KARPAS-299	NVTjToY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTRwM{GwNVMh\|ryP	MoLRV2FPT0WU
SNU-C2B	NFn4PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnZcFU6UUN3ME20MlM1Pjh4IN88US=>	MUDTRW5ITVJ?
LU-139	M{\ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHEVFU1UUN3ME20MlM4OjR5IN88US=>	Mlz5V2FPT0WU
HCC1937	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTRwM{e5PVMh\|ryP	NGfnRnBUSU6JRWK=
GR-ST	NYqzSll[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTVSWZKSzVyPUSuOFMyQCEQvF2=	NGXnNHZUSU6JRWK=
SK-OV-3	M4e2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIL3WVhKSzVyPUSuOFYxPDJizszN	MXHTRW5ITVJ?
A172	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFy4Z29KSzVyPUSuOVU2OjFizszN	MWnTRW5ITVJ?
NB10	NWm1SY1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGToPZhKSzVyPUSuOVk4QDFizszN	M2HwNnNCVkeHUh?=
P30-OHK	M2Dsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvOTWM2OD12LkixPVI6KM7:TR?=	M33hVnNCVkeHUh?=
KYSE-520	M1zrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXroOHBYUUN3ME20Mlg5ODF6IN88US=>	NWnnfG1zW0GQR1XS
KNS-62	M4LuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLWb\|A{UUN3ME20MlkxQDB5IN88US=>	MYjTRW5ITVJ?
ES1	NWnLe3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTRwOU[wN\|Uh\|ryP	NEnUc\|RUSU6JRWK=
KOSC-2	M13FdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXj2[VBQUUN3ME20Mlk6QTV7IN88US=>	MXvTRW5ITVJ?
TE-9	NUfabGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn1fXFNUUN3ME21MlAyPTJ3IN88US=>	NV3aR\|ZFW0GQR1XS
NCI-H1838	M3;Icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnZTWM2OD13LkCyNFc3KM7:TR?=	M1zuWHNCVkeHUh?=
KP-N-YN	NFzRPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3hWYtKSzVyPUWuNVI2QTFizszN	MV;TRW5ITVJ?
ALL-PO	NX7aR5BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTVwMkK1PFch\|ryP	NWTHcGQ6W0GQR1XS
NOMO-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH63XoVKSzVyPUWuNlMyPzZizszN	M2LuZnNCVkeHUh?=
CGTH-W-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXlTWM2OD13LkO4OVg1KM7:TR?=	NGjiUppUSU6JRWK=
ATN-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\vXYZKSzVyPUWuOFEyQDRizszN	M4DES3NCVkeHUh?=
AGS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrQTWM2OD13LkS5OlE5KM7:TR?=	NU\lZ\|RnW0GQR1XS
SW13	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXaUmJKSzVyPUWuOVMzPjVizszN	NIH3b2lUSU6JRWK=
SW1990	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1GxdGlEPTB;NT62NlI5PSEQvF2=	NFjOboZUSU6JRWK=
BFTC-905	Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TxXGlEPTB;NT62OVg4QCEQvF2=	M3r6ZXNCVkeHUh?=
RMG-I	M2HrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETwR\|lKSzVyPUWuOlU6PDJizszN	Mnf6V2FPT0WU
HD-MY-Z	NFvPWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rYNWlEPTB;NT62PFU5OSEQvF2=	NGDaNWhUSU6JRWK=
HCC1187	NGHvfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TvXGlEPTB;NT63NVA{OiEQvF2=	NVjSPHNuW0GQR1XS
HCC2998	M4fF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTVTWM2OD13LkexPFc4KM7:TR?=	NWTCZ\|dqW0GQR1XS
RT-112	NGLVTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTVwOUCyOFUh\|ryP	NEDrbnFUSU6JRWK=
CAKI-1	NYPhRXZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELpdo1KSzVyPU[uNFA6QDVizszN	M2nHe3NCVkeHUh?=
HDLM-2	NEPTUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4WxO2lEPTB;Nj6wNVQ5QSEQvF2=	MlP1V2FPT0WU
TE-10	NYXseFZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFL4PZRKSzVyPU[uNFQ5OzNizszN	NHTXe3RUSU6JRWK=
KE-37	M1XkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTZwMEeyOVgh\|ryP	NEjvfZZUSU6JRWK=
RCM-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXFbVVjUUN3ME22MlA4PzF7IN88US=>	NUnuZ5FsW0GQR1XS
Mewo	M2K1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknrTWM2OD14LkGxOFg4KM7:TR?=	MoG2V2FPT0WU
L-428	M3Tm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rudWlEPTB;Nj6xPFA{PyEQvF2=	MlnlV2FPT0WU
8-MG-BA	NUPIT4RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTZwMUmzO\|kh\|ryP	NVPBNmRoW0GQR1XS
SK-MEL-28	M4j2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HDcmlEPTB;Nj6yNFk3PyEQvF2=	M{jwcnNCVkeHUh?=
VA-ES-BJ	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTZwM{C0OlIh\|ryP	NVnKZXR6W0GQR1XS
CAL-120	M2TpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTJWJN1UUN3ME22MlQ2OTZ{IN88US=>	MnfXV2FPT0WU
GAMG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LJPGlEPTB;Nj61NFYzKM7:TR?=	M2XrenNCVkeHUh?=
MSTO-221H	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoG0TWM2OD14LkWxNVch\|ryP	Ml:5V2FPT0WU
GCT	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD5e21pUUN3ME22MlU{Ozh5IN88US=>	NIewUWVUSU6JRWK=
SH-4	NYfmcJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDTeXdiUUN3ME22MlU5QDR2IN88US=>	MW\TRW5ITVJ?
Calu-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PwPWlEPTB;Nj62OVU3QCEQvF2=	MlviV2FPT0WU
SK-HEP-1	M3P3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLSW41KSzVyPU[uO\|E4PTNizszN	M2[3bnNCVkeHUh?=
PFSK-1	M374V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PjeGlEPTB;Nj63N\|Q4QCEQvF2=	NWCybFd3W0GQR1XS
NB12	NX3xSm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjpTWM2OD14Lke4OFA1KM7:TR?=	NELLbXlUSU6JRWK=
A388	NH;kcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\GZmlEPTB;Nj64PVUzKM7:TR?=	NXvIbXNTW0GQR1XS
KLE	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLp[XZKSzVyPU[uPVY2OTZizszN	MWDTRW5ITVJ?
TE-11	M1\uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4G3OmlEPTB;Nz6wOFk3PyEQvF2=	NX[yeI1TW0GQR1XS
NCI-H2405	M3W1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[0TI5KSzVyPUeuNFg{QTNizszN	NWHlc5c2W0GQR1XS
OVCAR-4	NUmydI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTdwMUWzOUDPxE1?	NEP2c5ZUSU6JRWK=
KP-N-YS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjvdVBEUUN3ME23MlE5OTRizszN	MlvBV2FPT0WU
NOS-1	NEDPWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF72UY1KSzVyPUeuNlU5OjhizszN	MXzTRW5ITVJ?
DMS-114	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rkWGlEPTB;Nz6yPVY{OSEQvF2=	MmXYV2FPT0WU
NCI-H2030	M3Hhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfER5p[UUN3ME23MlM{Pjl6IN88US=>	NGHuSGNUSU6JRWK=
HEL	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1:ybGlEPTB;Nz6zO\|UzOSEQvF2=	NFfVUYlUSU6JRWK=
CAL-62	NWT2[3A1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3I[ZpQUUN3ME23MlM6QDZ4IN88US=>	NILGdJBUSU6JRWK=
COLO-668	Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHUeJpKSzVyPUeuOFM6PjdizszN	MW\TRW5ITVJ?
SKG-IIIa	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTdwNEWzPFEh\|ryP	MlrIV2FPT0WU
HCC1419	M{PNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTdwNE[4N\|Mh\|ryP	NWPqc3NsW0GQR1XS
OS-RC-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTdwNEm4PVQh\|ryP	NEnZXJlUSU6JRWK=
COLO-829	NUTBfnhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nWTGlEPTB;Nz62OlQ3OyEQvF2=	M4TTS3NCVkeHUh?=
NB13	MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTdwOEK2Olch\|ryP	MnPQV2FPT0WU
DK-MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NID3VHBKSzVyPUeuPFMzODFizszN	NVvNRllEW0GQR1XS
SHP-77	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[0TWM2OD15Lki2OlU{KM7:TR?=	MYLTRW5ITVJ?
NCI-H661	M1jaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRThwMEW4Olch\|ryP	NU\UV\|Y1W0GQR1XS
AM-38	NGTVPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPhWXlSUUN3ME24MlE3OjhizszN	M1i3VHNCVkeHUh?=
VM-CUB-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LYdWlEPTB;OD6xO\|AzQSEQvF2=	NHfub2dUSU6JRWK=
KYSE-70	NUPxRYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRThwMUm3OlEh\|ryP	M4LJSXNCVkeHUh?=
5637	NXv2U5ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGf2TWtKSzVyPUiuN\|ExPTVizszN	NE\pS3ZUSU6JRWK=
TGBC11TKB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjwOoVLUUN3ME24MlQ3OTZ2IN88US=>	NX;WZ5dvW0GQR1XS
EGI-1	M2TNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{n2WGlEPTB;OD62NFA5QCEQvF2=	Moj4V2FPT0WU
D-392MG	NH3ZNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVey[lU3UUN3ME24MlY3OjF2IN88US=>	M2m4fXNCVkeHUh?=
A673	M4H3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\0UmlEPTB;OD62O\|YyOSEQvF2=	MoH1V2FPT0WU
COLO-792	M4TUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\Ib4hKSzVyPUiuO\|Q6PDZizszN	MY\TRW5ITVJ?
NCI-H1792	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfubFZKSzVyPUiuPFg6ODNizszN	NEPtT4ZUSU6JRWK=
LS-1034	NUDre3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3nTWM2OD16Lkm0OlUzKM7:TR?=	MmDXV2FPT0WU
D-566MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17WbGlEPTB;OT6wNVgyKM7:TR?=	M4DmWnNCVkeHUh?=
NCI-H226	M2H5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:2RWhKSzVyPUmuNFkh\|ryP	MnHyV2FPT0WU
ChaGo-K-1	NEPYbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoT3TWM2OD17LkGwOVc6KM7:TR?=	MmTEV2FPT0WU
NCI-H2228	MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnPWWNKSzVyPUmuNVExQDFizszN	MVrTRW5ITVJ?
RPMI-8226	NWDDVppPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTlwMUGzNFQh\|ryP	MlvnV2FPT0WU
BFTC-909	M4rZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDWeHRwUUN3ME25MlE5Ojl5IN88US=>	MVfTRW5ITVJ?
HPAF-II	M2[1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTlwMkK1NVgh\|ryP	MUXTRW5ITVJ?
Capan-2	M4\RdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHwTWM2OD17LkSwNVA6KM7:TR?=	M13ZcHNCVkeHUh?=
IA-LM	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTlwNEG5OlYh\|ryP	MWrTRW5ITVJ?
KP-4	NWXWWFdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLrTWM2OD17LkS4PFM5KM7:TR?=	M1y0WnNCVkeHUh?=
A101D	M2TzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTlwNUG3NVkh\|ryP	M2\ofnNCVkeHUh?=
EFO-21	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHi4WoFKSzVyPUmuOVg4OzVizszN	NXrJUJhZW0GQR1XS
C32	NV7BPGgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzzTWM2OD17Lk[zN\|Qh\|ryP	Mn\ZV2FPT0WU
SW837	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfWTWM2OD17Lki0PFIh\|ryP	NFrRZpBUSU6JRWK=
OCI-AML2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHGUmxoUUN3ME25Mlg3QTZizszN	NV;VV3lnW0GQR1XS
NCI-H1355	MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITEO5ZKSzVyPUmuPVQxQDhizszN	MlToV2FPT0WU
NCI-H2342	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vFeWlEPTB;MUCuNFE2PSEQvF2=	M4n5UXNCVkeHUh?=
A204	NUfESXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTFyLkC0OlYh\|ryP	NIP2WI1USU6JRWK=
CAL-51	M3PYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDxOHNKSzVyPUGwMlA5PzdizszN	Ml3YV2FPT0WU
HCE-4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni1TWM2OD1zMD6xNVIzKM7:TR?=	NUfINpVoW0GQR1XS
NCI-H810	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXlcmJNUUN3ME2xNE4yPTl5IN88US=>	MVjTRW5ITVJ?
DJM-1	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PibmlEPTB;MUCuNVc{OiEQvF2=	M1fvcHNCVkeHUh?=
SK-UT-1	NVzZOHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\RdWlEPTB;MUCuNlU4PCEQvF2=	M{GxcnNCVkeHUh?=
U031	NV2wPWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\tUmlEPTB;MUCuNlY5PiEQvF2=	M2DOTnNCVkeHUh?=
YH-13	NFTHd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rncmlEPTB;MUCuN\|A2PyEQvF2=	Mm\SV2FPT0WU
K5	M2f6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3kTWM2OD1zMD6zN\|k2KM7:TR?=	NFf2dnVUSU6JRWK=
HEC-1	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvq[HBLUUN3ME2xNE41ODhzIN88US=>	MlXRV2FPT0WU
A2058	NHnXPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7ofWJKSzVyPUGwMlU1QTFizszN	NV7jSlZVW0GQR1XS
SW962	NXLvdGhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\xTWM2OD1zMD62NlA1KM7:TR?=	M1u1V3NCVkeHUh?=
VMRC-RCZ	NFXsUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvpdnpGUUN3ME2xNE43PzR7IN88US=>	NWLtclUyW0GQR1XS
D-336MG	M1rtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTFyLkewNFUh\|ryP	Mn21V2FPT0WU
LXF-289	M{DCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4GwN2lEPTB;MUCuO\|k3PyEQvF2=	NIXKPGNUSU6JRWK=
SW900	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTFyLkiyNlgh\|ryP	NXnaUIR6W0GQR1XS
K-562	NGPwO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTFyLkizPVUh\|ryP	NYD5OZpLW0GQR1XS
HCC38	NEXKclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD0TWM2OD1zMD65O\|E3KM7:TR?=	M1G1S3NCVkeHUh?=
SF-295	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInnbWRKSzVyPUGwMlk6ODJizszN	NXXkfo1uW0GQR1XS
LB831-BLC	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rFcmlEPTB;MUGuNlU2PiEQvF2=	NX\uW5hIW0GQR1XS
FTC-133	NH;IenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfafI81UUN3ME2xNU4{ODhzIN88US=>	Mn3ZV2FPT0WU
HCC1954	NFjQTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTFzLkSzOkDPxE1?	MkLYV2FPT0WU
GOTO	NHLEZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;Vc2lEPTB;MUGuOVIxPiEQvF2=	NV3Kc5Q1W0GQR1XS
LS-411N	NIrnTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDj[lJKSzVyPUGxMlYyODFizszN	MXfTRW5ITVJ?
RPMI-7951	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkeyTWM2OD1zMT62N\|Q5KM7:TR?=	MkS5V2FPT0WU
NCI-H1299	Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnrVGZxUUN3ME2xNU43PjR5IN88US=>	NIjtZYhUSU6JRWK=
MLMA	NY\6fWpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTFzLk[5PVch\|ryP	NXftfHdRW0GQR1XS
MMAC-SF	NEjkcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[wXWlEPTB;MUGuO\|I2OiEQvF2=	NVToNWZTW0GQR1XS
UM-UC-3	M1HIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTiWpV4UUN3ME2xNU44PDJzIN88US=>	MV\TRW5ITVJ?
SCC-9	M{HnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFzLkixOVEh\|ryP	M4jmUHNCVkeHUh?=
HOS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\GRYxKSzVyPUGxMlg3QDNizszN	NYHNTFNrW0GQR1XS
OE19	M1XWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLJ[llKSzVyPUGxMlk{PjdizszN	M1ju[XNCVkeHUh?=
Mo-T	NXP2UWxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfYOpRKSzVyPUGxMlk2PDFizszN	M3PBV3NCVkeHUh?=
CAMA-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfhTWM2OD1zMj6xOlM{KM7:TR?=	MmXPV2FPT0WU
U-118-MG	NVjSd4p2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTF{LkK0OFEh\|ryP	MlezV2FPT0WU
KS-1	M2X2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Pl[mlEPTB;MUKuNlg{OiEQvF2=	NWLI[otuW0GQR1XS
JAR	M1W4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDucWJKSzVyPUGyMlM{PjlizszN	NYLz[JpnW0GQR1XS
ABC-1	M1PhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF{LkO0NUDPxE1?	NGmyVG5USU6JRWK=
Daoy	NXyzd3BjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTF{LkS1OFIh\|ryP	MkTlV2FPT0WU
C3A	M3n6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTF{LkW3PFUh\|ryP	MVfTRW5ITVJ?
GT3TKB	NXvkUVFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NET5OHZKSzVyPUGyMlY{OjdizszN	MYnTRW5ITVJ?
DMS-273	NGXLNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3NTWM2OD1zMj64OlM{KM7:TR?=	NWDBZ2lYW0GQR1XS
G-361	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXLVZJMUUN3ME2xNk46OTJ7IN88US=>	MnSzV2FPT0WU
RH-18	NUnvW212T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHDb4dLUUN3ME2xN{4zQTZ{IN88US=>	NFmwUmxUSU6JRWK=
SN12C	M1LycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTF\|LkO4NFgh\|ryP	NUfWSolMW0GQR1XS
NCI-H1993	M1r4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUf3blZEUUN3ME2xN{41Ojh3IN88US=>	M{XBdHNCVkeHUh?=
LOXIMVI	NGriUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTF\|Lk[xOVEh\|ryP	NIPlV\|lUSU6JRWK=
SK-PN-DW	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYT3SWo5UUN3ME2xN{45PDJ5IN88US=>	Mo\aV2FPT0WU
KALS-1	MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF\|Lki1NlUh\|ryP	MV\TRW5ITVJ?
LAN-6	NWPDcGt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrWWI9xUUN3ME2xOE4zPTNizszN	NVTMNFZjW0GQR1XS
A549	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7FTWM2OD1zND60O\|EzKM7:TR?=	Mn7sV2FPT0WU
RD	MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDkTWM2OD1zND60PFE{KM7:TR?=	NXqyUVlpW0GQR1XS
TGBC1TKB	M3S3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LKUWlEPTB;MUSuOlYyPSEQvF2=	MXPTRW5ITVJ?
NCI-H630	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTF2Lkm0Olch\|ryP	M3XySXNCVkeHUh?=
MIA-PaCa-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fINmlEPTB;MUSuPVY6KM7:TR?=	NF;2eHZUSU6JRWK=
NCI-H1755	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknwTWM2OD1zND65PVU{KM7:TR?=	NHy5OpdUSU6JRWK=
MOLT-4	M4jRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzyZ5dKSzVyPUG1MlA1QTdizszN	M4Lz[nNCVkeHUh?=
CW-2	NYjp[\|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnBTWM2OD1zNT6xOFIyKM7:TR?=	MULTRW5ITVJ?
COLO-320-HSR	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTF3

研究领域

产品类型